Back to top
more

Exact Sciences (EXAS)

(Real Time Quote from BATS)

$60.00 USD

60.00
1,213,599

-3.24 (-5.12%)

Updated Apr 25, 2024 09:45 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View

Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View

Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.

Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note

In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.

Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up

Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.

Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised

Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Here's Why You Should Retain Prestige Consumer (PBH) Stock Now

The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.

ICON (ICLR) Gains From New Offerings, Strategic Acquisitions

ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.

Why Exact Sciences (EXAS) Dipped More Than Broader Market Today

Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.

Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract

Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).

Myriad Genetics (MYGN) Announces Favorable Research Results

Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.

Zacks Investment Ideas feature highlights: Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies

Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies are part of the Zacks Investment Ideas article.

Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know

Exact Sciences (EXAS) closed at $73.60 in the latest trading session, marking a -0.89% move from the prior day.

Derek Lewis headshot

3 Buy-Rated Stocks Flexing Relative Strength

While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three carrying a favorable Zacks Rank.

Neogen (NEOG) Q3 Earnings Miss Estimates, Gross Margin Expands

Neogen's (NEOG) third-quarter fiscal 2024 results reflect solid core revenue growth in both segments.

Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising

Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.

Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%

The mean of analysts' price targets for Exact Sciences (EXAS) points to a 53.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM

Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.